» Articles » PMID: 24528021

Roles of PTEN (Phosphatase and Tensin Homolog) in Gastric Cancer Development and Progression

Overview
Specialty Oncology
Date 2014 Feb 18
PMID 24528021
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer is highly invasive, aggressively malignant, and amongst the most prevalent of all forms of cancer. Despite improved management strategies, early stage diagnosis of gastric cancer and accurate prognostic assessment is still lacking. Several recent reports have indicated that the pathogenesis of gastric cancer involves complex molecular mechanisms and multiple genetic and epigenetic alterations in oncogenes and tumor suppressor genes. Functional inactivation of the tumor suppressor protein PTEN (Phosphatase and Tensin Homolog) has been detected in multiple cases of gastric cancer, and already shown to be closely linked to the development, progression and prognosis of the disease. Inactivation of PTEN can be attributed to gene mutation, loss of heterozygosity, promoter hypermethylation, microRNA- mediated regulation of gene expression, and post-translational phosphorylation. PTEN is also involved in mechanisms regulating tumor resistance to chemotherapy. This review provides a comprehensive analysis of PTEN and its roles in gastric cancer, and emphasizes its potential benefits in early diagnosis and gene therapy-based treatment strategies.

Citing Articles

Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to "double invasion": an analytical approach utilizing lasso-cox regression.

Wang L, Chang Y, Ma J, Qu W, Li Y BMC Cancer. 2025; 25(1):381.

PMID: 40022037 PMC: 11871700. DOI: 10.1186/s12885-025-13810-z.


Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.

Li Z, Zhao H, Hu H, Shang H, Ren Y, Qiu W Chin J Cancer Res. 2024; 36(3):306-321.

PMID: 38988489 PMC: 11230884. DOI: 10.21147/j.issn.1000-9604.2024.03.07.


Exploring the Therapeutic Effects of Koidz against Human Gastric Cancer.

Choi N, Choi W, Zhu A, Park J, Kim Y, Hong J Nutrients. 2024; 16(7).

PMID: 38612999 PMC: 11013299. DOI: 10.3390/nu16070965.


, , microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics.

Travis G, McGowan E, Simpson A, Marsh D, Nassif N Cancers (Basel). 2023; 15(20).

PMID: 37894321 PMC: 10605164. DOI: 10.3390/cancers15204954.


Structure-Based Profiling of Potential Phytomolecules with AKT1 a Key Cancer Drug Target.

Mirza Z, Karim S Molecules. 2023; 28(6).

PMID: 36985568 PMC: 10051420. DOI: 10.3390/molecules28062597.